The first gene therapy to treat a rare blood disorder is one step closer to approval Friday following a recommendation by European officials.
Lentiglobin, the gene therapy for beta-thalassemia developed by Cambridge, Mass.-based Bluebird Bio, was recommended for approval by the Committee for Medicinal Products for Human Use (CHMP), the drug-reviewing arm of the European Medicines Agency. A final approval decision is expected within the next three months.
About the Author Reprints
Please update me of the approval and how to get it started.